East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …

Clinical experiences have suggested that East Asians show the higher risk of warfarin-
related intracranial hemorrhage compared with Westerners. Therefore, different target of the …

Background Prolonged dual anti-platelet therapy (DAPT) is intended to reduce ischaemic
events, at the cost of an increased bleeding risk in patients undergoing percutaneous …

Background Prior reports indicate that the effect of P2Y12 inhibitors may be different in East
Asian patients (“East Asian paradox”); therefore, understanding the outcomes associated …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

In 2019, the Japanese Circulation Society published 2 guidelines in the field of coronary
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …

Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with
acute coronary syndromes and in those undergoing percutaneous coronary intervention …

BACKGROUND: Atherothrombosis is a common condition affecting individuals worldwide.
Its impact on different ethnic groups receiving evidence-based therapy is unclear. We aimed …

Background In the PLATO trial, ticagrelor was superior to clopidogrel in reducing
cardiovascular events among patients with acute coronary syndrome (ACS) at the expense …